文献速递前列腺癌

2010至2015年美国低危前列腺癌主动监测/观察等待在社会经济地位中的趋势

United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-10-07

基于SEER前列腺癌主动监测/观察等待数据库,纳入2010至2015年50,302例低危局限性前列腺癌男性,分析主动监测/观察等待(AS/WW)使用随社会经济地位(SES)三分位的变化趋势。结果显示AS/WW使用率随SES升高而增加(低、中、高三分位分别为24.6%、25.3%、30.5%),2010至2015年各SES组AS/WW使用率均显著上升,但2015年低SES组接受AS/WW的调整比值比仍显著低于高SES组(aOR 0.73, 95%CI 0.64-0.83, P<0.001)。

要点

  • 低危前列腺癌AS/WW使用率随SES三分位升高而增加,低SES组最低。
  • 2010至2015年各SES组AS/WW使用率均显著上升,呈线性趋势(P<0.001)。
  • 2015年低SES组AS/WW几率仍显著低于高SES组(aOR 0.73, 95%CI 0.64-0.83)。

核心结论

  • 美国低危前列腺癌AS/WW使用存在SES差异,低SES患者接受AS/WW的几率显著低于高SES组。
  • 尽管2010至2015年各SES组AS/WW使用率均上升,但低SES组仍处于较低水平。
  • 低SES相关因素可能成为AS/WW的障碍,需加以解决以减少低SES患者不必要治疗的风险。

研究设计与样本

  • 回顾性队列研究,使用SEER前列腺癌主动监测/观察等待数据库。
  • 纳入2010至2015年50,302例成年男性,均为低危局限性前列腺癌(临床T1-T2a、Gleason 6、PSA<10 ng/mL)。
  • SES采用经验证的Yost指数三分位(低:0-10,901;中:10,904-11,469;高:11,470-11,827)。
  • 采用多因素logistic回归计算SES三分位接受AS/WW的调整比值比(aOR)。

主要发现

  • 总体AS/WW使用率随SES三分位升高而增加:低24.6%、中25.3%、高30.5%(PTrend<0.001)。
  • 2010至2015年AS/WW使用率变化:低SES从11.2%升至37.3%,中SES从14.1%升至45.8%,高SES从17.6%升至46.4%(PTrends<0.001)。
  • 2015年中SES与高SES组AS/WW几率相当(aOR 0.96, 95%CI 0.83-1.11, P=0.55)。
  • 2015年低SES组AS/WW几率仍显著低于高SES组(aOR 0.73, 95%CI 0.64-0.83, P<0.001)。

关键数值与推荐

  • 低危局限性前列腺癌定义:临床T1-T2a、Gleason 6、PSA<10 ng/mL。
  • SES三分位Yost指数范围:低0-10,901;中10,904-11,469;高11,470-11,827。
  • 2015年中vs高SES组AS/WW的aOR 0.96(95%CI 0.83-1.11, P=0.55)。
  • 2015年低vs高SES组AS/WW的aOR 0.73(95%CI 0.64-0.83, P<0.001)。

临床怎么用

  • 临床决策中应关注低SES低危前列腺癌患者,识别并解决其接受AS/WW的障碍。
  • 对低SES患者加强AS/WW随访依从性支持和共享决策,以降低不必要治疗风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prospective evidence supports active surveillance/watchful waiting (AS/WW) as an efficacious management option for low-risk prostate cancer that avoids potential treatment toxicity. AS/WW schedules require regular follow-up and adherence, and it is unknown to what extent patient socioeconomic status (SES) may impact management decisions for AS/WW. We sought to determine whether AS/WW use in the United States differs according to patient SES. DESIGN: Using the Surveillance, Epidemiology, and End Results Prostate with AS/WW Database, all adult men diagnosed with localized low-risk prostate cancer (clinical T1-T2a, Gleason 6, and prostate-specific antigen <10 ng/mL) and managed with either AS/WW, radical prostatectomy, or radiotherapy were identified between 2010 and 2015. SES tertile was measured by the validated Yost Index (low: 0-10,901; middle: 10,904-11,469; high: 11,470-11,827). AS/WW trends were defined across SES tertiles from 2010 to 2015. Logistic multivariable regression defined adjusted odds ratios (aOR) for receipt of AS/WW by SES tertile. RESULTS: In 50,302 men, AS/WW use was higher with increasing SES tertile (24.6, 25.3, and 30.5% for low, middle, and high SES tertiles, respectively; PTrend (SES) <0.001). From 2010 to 2015, AS/WW use in the low, middle, and high SES tertiles increased from 11.2 to 37.3%, 14.1 to 45.8%, and 17.6 to 46.4%, respectively (PTrends <0.001). By 2015, likelihood of AS/WW became comparable among the middle vs. high SES tertiles (aOR 0.96, 95% confidence interval (CI): 0.83-1.11, P = 0.55), but remained lower among the low vs. high SES tertile (aOR 0.73, 95% CI: 0.64-0.83, P < 0.001). CONCLUSIONS: AS/WW use for low-risk prostate cancer in the US differs by SES. Despite increases in AS/WW across SES from 2010 to 2015, patients from low SES received significantly lower rates of AS/WW compared with higher SES groups. SES may therefore influence management decisions, where factors associated with low SES might act as a barrier to AS/WW, and may need to be addressed to reduce any disproportionate risk of unnecessary treatment to lower SES patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Butler SS, Loeb S, Cole AP, et al. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2019. PMID: 31591454. doi:10.1038/s41391-019-0175-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。